RICHMOND, VA — Bright Path Pharmaceuticals, LLC (privately held) today announced that the Medicines for All Institute, a joint venture between Virginia Commonwealth University and the Gates Foundation, has selected BPP as its’ first commercial innovation manufacturing partner.
Dr. Frank Gupton, Executive Director of Medicine for All Institute, “We are very excited about the company’s innovations and are anxious to work together to provide better access to medicines at a more affordable price point.”
Anthony Quinones, Chief Impact Officer of Bright Path Pharmaceuticals, said, “The company is thrilled to join Dr. Gupton and Med4All as strategic partners.” Mr. Allen stated, “As the former North American Head of Chemical Engineering and Manufacturing for Boehringer Ingelheim, Dr. Gupton adds a lot of creditability to our manufacturing initiatives.”
About Bright Path Pharmaceuticals, LLC
Bright Path Pharmaceuticals, LLC is a developmental stage bio-pharmaceutical manufacturing company, dedicated to developing best-in-class continuous-flow manufacturing for the pharmaceutical sector. For more information, please visit www.brightpathrx.com.
To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about Bright Path Pharmaceuticals’ plans, objectives, expectations and intentions with respect to cash flow requirements, future operations and products, and development activities, and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause Bright Path Pharmaceuticals’ actual results to be materially different than those expressed in or implied by Bright Path Pharmaceuticals’ forward-looking statements. For Bright Path Pharmaceuticals, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the success and design of manufacturing facilities; and Bright Path Pharmaceuticals’ need for and ability to obtain additional financing. Bright Path Pharmaceuticals undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.